Skip to main content
Services
Technology
Technology
YoctoReactor
Binder Trap Enrichment ®(BTE)
Cellular Binder Trap Enrichment®(cBTE)
Company
Company
Partners
Career
Art
Partners
Partners
Aurigene Pharmaceutical Services
SARomics Biostructures
Boo Kyung S·M Co.
Resources
Resources
Publications
FAQ
Conferences
News
Articles
Posters
Contact
Inquiry
Services
Services
Small molecule drug discovery for even hard-to-drug targets - identify inhibitors, binders and modulators
In living cell
In vitro
Molecular Glue Direct
In living cell
In vitro
PPI Inhibitor Direct
In living cell
In vitro
Integral membrane proteins
In living cell
In vitro
Selectivity Direct – multiplexed screening of target and anti-targets
In living cell
In vitro
Express - optimized for fast turn-around-time
In living cell
In vitro
Snap - easy, fast, and affordable
In living cell
In vitro
Technology
Technology
YoctoReactor
Accelerate molecular discovery with YoctoReactor
®
YR Libraries – advanced automation for efficient screening and optimization.
Read more
Binder Trap Enrichment
Streamline drug discovery with Binder Trap Enrichment
®
– enabling precise and efficient identification of high-affinity binders.
Read more
Cellular Binder Trap Enrichment
Enhance drug discovery with Cellular Binder Trap Enrichment
®
– enabling efficient identification of cellular target binders.
Read more
Partnering with
Vipergen
From straightforward Fee-For-Service to comprehensive joint ventures, we provide flexible partnership structures to align with your project’s distinct needs.
Explore our services
Resources
Articles
DNA-Encoded Libraries
DNA-Encoded Libraries
Medicinal Chemistry Services for DNA-Encoded Library Screening
The Advantages of Using DNA-Encoded Libraries (DELs) in Hit Identification Compared to Traditional High-Throughput Screening (HTS)
DNA-Encoded Libraries vs. Fragment-Based Screening: Pros and Cons
DNA Encoded Libraries: Principle of DNA-Compatible Chemical Reactions for High-Throughput Small Molecule Discovery
Understanding DEL Screening: From Target Binding to Hit Validation
Synthesis of DNA Encoded Libraries for Drug Discovery
Hit Identification & Screening
Hit Identification & Screening
Molecular Display Systems in Drug Discovery: Principles, Platforms, and Applications
From Target to Therapy: A Comprehensive Overview of the Drug Discovery Workflow
High-Throughput Screening in Drug Discovery
Revolutionizing Research with Chemical Libraries
Hit Identification in Drug Discovery
Target Classes
Target Classes
Structural Proteins as Drug Targets
Ion Channels as Drug Targets
Receptors as Drug Targets
Unlocking the Secrets of Kinases in Cellular Regulation
Transcription Factor Inhibitors: From “Undruggable” to Drug Discovery Reality
Protein-Protein Interactions in Disease and Pharmacology: Unlocking New Frontiers in Drug Discovery
Therapeutic Strategies
Therapeutic Strategies
Spatial Pharmacology: Organelle Targeting and Condensate-Mediated Drug Discovery
Next-Generation Targeted Protein Degradation: Beyond Classical PROTACs
Synthetic Lethality and Context-Dependent Cancer Targeting
RNA-Targeted Small Molecules and Translation-Modulating Therapeutics
Autophagy and Lysosome-Based Targeted Degradation Technologies
Choosing the Right Inhibitor Strategy: Antagonists, Agonists, Allosteric & Covalent Inhibitors in Modern Drug Discovery
Xenopus Oocytes in Human Protein Research and Drug Discovery
Small Molecule Drugs: Principles of Drug-Likeness and Molecular Design for Optimal Therapeutic Efficacy
How Molecular Glue is Transforming Drug Discovery
Targeted Protein Degradation
Platforms & Assays
Platforms & Assays
Unlocking the Potential of Cell-Based Assays in Modern Scientific Research
Therapeutic Areas
Therapeutic Areas
CNS Drug Discovery
Cancer Drug Discovery
Company
Get In Touch
Menu
Vipergen ApS
Gammel Kongevej 23A
1
st
floor
1610 Copenhagen
Denmark
VAT: DK28851758
info@vipergen.com
Partnering with
Vipergen
From straightforward Fee-For-Service to comprehensive joint ventures, we provide flexible partnership structures to align with your project’s distinct needs.
Explore our services
Partners
Aurigene Pharmaceutical Services
SARomics Biostructures
Boo Kyung S.M Co.
Company
About us
Team
In brief
Career
Art
Resources
Publications
FAQ
Conferences
News
Articles
Posters
Latest news
Vipergen launches new DEL series with Lib100 and updates Series 50 to Lib058
October 7, 2025
SARomics Biostructures and Vipergen collaborate to offer enhanced drug discovery services
November 11, 2024
Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.
April 19, 2024
News
October 7, 2025
Vipergen launches new DEL series with Lib100 and updates Series 50 to Lib058
Read more
November 11, 2024
SARomics Biostructures and Vipergen collaborate to offer enhanced drug discovery services
Read more
April 19, 2024
Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.
Read more
June 15, 2022
Vipergen and LEO Pharma Partner for DNA Encoded Library (DEL)-Based Drug Discovery for Dermatology Indications
Read more
April 4, 2022
Vipergen Establishes DNA Encoded Library (DEL)-Based Drug Discovery Partnership with Theseus Pharmaceuticals Focused on Targeted Cancer Therapies
Read more
December 21, 2021
Vipergen Establishes Research Partnership with Bayer to Discover Novel Compounds for Pharmaceuticals and More Sustainable Crop Protection Solutions
Read more
November 23, 2021
Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases
Read more
November 15, 2021
Vipergen Establishes Research Partnership with ALK Focused on DNA-Encoded Library (DEL)-Based Drug Discovery for Allergy Immunotherapies
Read more
October 21, 2021
BASF and Vipergen accelerate targeted research and development of sustainable crop protection products
Read more
September 14, 2021
Vipergen Establishes Research Partnership with PhoreMost Focused on DNA Encoded Library (DEL)-Based Drug Discovery
Read more
May 17, 2021
Vipergen Establishes Partnership with Anavo Therapeutics to Support Phosphatase-Targeted Discovery Programs
Read more
March 17, 2021
Vipergen strengthens leadership by appointing Dr Leif Kongskov Larsen as Director of Biology and promoting Dr Allan Beck Christensen to Director of Screening Technologies
Read more
February 17, 2021
Vipergen Publishes First Technology for Screening DNA-Encoded Small-Molecule Libraries (DELs) Inside Living Cells
Read more
December 1, 2020
Casma Therapeutics and Vipergen Enter Into Drug Discovery Agreement
Read more
November 6, 2020
Commercial release of the first technology for DEL screening inside a living cell
Read more
December 20, 2016
Vipergen enters into multi-target drug discovery agreement with Merck
Read more
June 22, 2016
Vipergen enters into multi-target drug discovery agreement with Daiichi Sankyo
Read more
June 19, 2016
Vipergen enters into multi-target drug discovery agreement with Gilead
Read more
December 21, 2015
Vipergen enters into multi-target collaboration with Europes largest biopharmaceutical company
Read more
December 18, 2015
Vipergen enters into multi-target drug discovery agreement with Amgen
Read more
